Copper-delivery drug boosts brain cleanup and memory in Alzheimer's mouse model
TL;DR
Monash University researchers used Cu(ATSM), a copper-delivery compound, to repair the brain’s blood–brain barrier by increasing the P-glycoprotein clearance pumps, which reduced toxic amyloid-beta by about 42% and improved long-term spatial memory by roughly 44% in an APP/PS1 mouse model over 56 days, suggesting copper-based biometal therapy could be a promising route for early symptomatic Alzheimer's disease with potential for quicker human testing due to prior safety evaluations; future work aims to map the precise clearance mechanisms and pathways.
Topics:healthmedical-research#alzheimers-disease#blood-brain-barrier#copper-therapy#cuatsm#medical-research#p-glycoprotein
- Lab trials prove copper therapy enhances cognitive function and spatial learning News-Medical
- Copper drug restores memory and clears toxic Alzheimer’s proteins Monash University
- Research authors (IMAGE) EurekAlert!
- Copper drug Cu(ATSM) reduces Alzheimer’s proteins by 42 percent in preclinical study Drug Target Review
- A Copper Drug Cleared Toxic Proteins and Restored Memory in Alzheimer’s Mice ScienceBlog.com
Want the full story? Read the original reporting
Read on News-Medical